Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Study

 

Phase: 1b

Status: Ongoing

About

Phase 1b of a study of DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer


Details

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Daiichi Sankyo, Inc

NCT04042701